

**UNITED STATES DISTRICT COURT
DISTRICT OF NEW JERSEY**

**IN RE: PROTON-PUMP INHIBITOR
PRODUCTS LIABILITY
LITIGATION (NO. II)**

**2:17-MD-2789 (CCC)(LDW)
(MDL 2789)
and all member and related cases

JUDGE CLAIRE C. CECCHI**

**THIS DOCUMENT RELATES TO:
ALL ACTIONS**

**CASE MANAGEMENT ORDER NO. 109
(Docket Control Order)**

This Case Management Order (“CMO”) applies to all Plaintiffs alleging personal injury (and related) claims against Defendants AstraZeneca Pharmaceuticals LP, AstraZeneca LP, Merck Sharp & Dohme Corp., Merck & Co., Inc., and Merck & Co. D/B/A Merck Sharp & Dohme Corp. (collectively, the “AstraZeneca and Merck Defendants”) who have cases pending against the AstraZeneca and Merck Defendants as of the date this order is entered and are not settling under the voluntary settlement program, and all Plaintiffs with cases alleging personal injury (and related) claims against the AstraZeneca and Merck Defendants that are newly filed in, removed to, or transferred to this MDL after the entry of this order (“Litigating Plaintiffs”).

Consistent with the Court’s inherent authority to manage these judicial proceedings, and in light of the Master Settlement Agreement that the AstraZeneca and Merck Defendants and Plaintiffs’ Counsel entered into after over six years of litigation in this MDL, the Court will exercise its discretion to enter this Docket Control Order to efficiently manage any remaining cases against the AstraZeneca and Merck Defendants, while separately managing the litigation against any remaining defendants that are not subject to settlement agreements and/or a related stay.

This order requires all Litigating Plaintiffs to produce certain specified information regarding their claims and provides for expedited bifurcated discovery on statute of limitations, other time-based defenses, and causation issues, and related dispositive motion practice, prior to any further discovery. Litigating Plaintiffs who represent themselves *pro se* shall be bound by the requirements of this order and shall fully comply with all obligations required of counsel by this order, unless otherwise stated.

A. Background and Status of Proceedings

1. The events leading up to this litigation began in January 2016, when an epidemiological study by Lazarus et al. was published in *JAMA Internal Medicine*, reporting an association between the use of proton pump inhibitors (“PPIs”) and chronic kidney disease. The Lazarus study received widespread media coverage in news outlets such as the New York Times, Washington Post, CBS News, and Fox News. In April 2016, an epidemiological study by Xie et al. was published in the *Journal of the American Society of Nephrology*, reporting a similar association between PPIs and kidney disease. The Xie study generated further publicity in mainstream media outlets including CNN, ABC News, CBS News, and Fox News. In addition, a study by Peng et al. was published in *Medicine* in April 2016 and a study by Arora et al. was published in *BMC Nephrology* in August 2016.

As public awareness of a potential association between PPIs and kidney disease grew, personal injury lawsuits began to be filed. By February 2017, there were nearly 40 lawsuits pending in various federal courts alleging that the use of PPIs resulted in kidney disease. *See In re Proton-Pump Inhibitor Prods. Liab. Litig.*, 273 F. Supp. 3d 1360, 1361 (J.P.M.L. 2017). Over the next several months, more lawsuits were filed, and on August 2, 2017, the JPML established MDL No. 2789 (“the MDL”) to centralize cases against several defendants, including the AstraZeneca and

Merck Defendants, alleging kidney injuries arising from the use of PPIs. *Id.* More than 18,600 cases have been filed in, removed to, or transferred to the MDL over the past six years, and of these, approximately 17,950 cases have named one or more of the AstraZeneca and Merck Defendants.

2. As the Supreme Court of the United States has recognized, “[f]ederal courts possess certain inherent powers, not conferred by rule or statute, to manage their own affairs so as to achieve the orderly and expeditious disposition of cases.” *Goodyear Tire & Rubber Co. v. Haeger*, 581 U.S. 101, 107 (2017) (internal quotations omitted); *see also Haagensen v. Pennsylvania State Police*, 490 F. App’x 447, 454 (3d Cir. 2012). This power extends to, for example, “controlling and scheduling discovery, including orders affecting disclosures and discovery under Rule 26 and Rules 29 through 37,” “adopting special procedures for managing potentially difficult or protracted actions that may involve complex issues, multiple parties, difficult legal questions, or unusual proof problems,” and “facilitating in other ways the just, speedy, and inexpensive disposition of the action.” Fed. R. Civ. P. 16(c)(2)(F),(L),(P).

3. Case management is of the utmost importance in proceedings of this size. Indeed, multidistrict litigation “presents a special situation, in which the district judge must be given wide latitude with regard to case management in order to effectively achieve the goals set forth by the legislation that created the Judicial Panel on Multidistrict Litigation.” *In re Avandia Mktg., Sales Pracs. & Prods. Liab. Litig.*, 687 Fed. App’x 210, 214 (3d Cir. 2017) (affirming MDL court’s dismissal for failure to comply with an order requiring future plaintiffs to provide an expert report); *see also In re Asbestos Prods. Liab. Litig. (No. VI)*, 718 F.3d 236, 246 (3d Cir. 2013) (“[D]istrict judges must have authority to manage their dockets, especially during a massive litigation” (internal quotations and citations omitted)) (affirming MDL court’s dismissal of claims for failure to comply with discovery orders); *Chauvin v. Bayer Healthcare Pharmaceuticals, Inc.*, 860 Fed.

App'x 95, 96–97 (8th Cir. 2021) (“MDL courts are ‘given greater discretion to create and enforce deadlines in order to administrate the litigation effectively,’ which ‘includes the power to dismiss cases where litigants do not follow the court’s orders’”); *In re Guidant Corp. Implantable Defibrillators Prods. Liab. Litig.*, 496 F.3d 863, 866-68 (8th Cir. 2007) (“MDL courts must be given greater discretion to organize, coordinate and adjudicate [their] proceedings”) (affirming MDL court’s dismissal of claims for failure to comply with discovery orders); *In re Phenylpropanolamine Prods. Liab. Litig.* (“*In re PPA*”), 460 F.3d 1217, 1229, 1234 (9th Cir. 2006) (“administering cases in multidistrict litigation is different from administering cases on a routine docket”) (finding no abuse of discretion in MDL court’s dismissal of claims for failure to comply with discovery and product identification case management orders); *Freeman v. Wyeth*, 764 F.3d 806, 809-810 (8th Cir. 2014) (affirming MDL court’s dismissal of claims for failure to provide medical authorizations). This is particularly true with respect to managing discovery and taking actions designed to move the cases “in a diligent fashion toward resolution by motion, settlement or trial.” *In re PPA*, 460 F.3d at 1232.

4. During the course of these MDL proceedings, this Court has exercised its discretion and inherent authority and established “separate discovery ... tracks, to manage pretrial proceedings efficiently.” *In re Proton-Pump Inhibitor*, 261 F. Supp. 3d at 1354; *see also* CMO 21, ECF No. 244; CMO 54, ECF No. 690; CMO 74, ECF No. 781; Fed. R. Civ. P. 16(c).

5. The Court is aware that, without admission of fault or liability, the AstraZeneca and Merck Defendants have entered into a Master Settlement Agreement to resolve cases alleging personal injury (and related) claims against them related to PPI products. The settlement comes over six years after the establishment of this MDL. During that time, the parties have engaged in and

completed general liability discovery, a robust bellwether selection process, and general and case-specific expert discovery.

6. Docket control orders “have been routinely used by courts to manage mass tort cases.” *In re Vioxx Prod. Liab. Litig.*, 557 F. Supp. 2d 741, 743 (E.D. La. 2008) (Fallon, J.). Appellate courts regularly uphold such orders in MDL cases.¹

7. Such docket control orders may be particularly appropriate when a defendant has taken steps to settle a significant portion of the claims pending against it.²

¹ See, e.g., *In re Avandia*, 687 Fed. App’x at 214; *Chauvin*, 860 Fed. App’x at 96–97 (“MDL courts are ‘given greater discretion to create and enforce deadlines in order to administrate the litigation effectively,’ which ‘includes the power to dismiss cases where litigants do not follow the court’s orders’” (affirming MDL court’s dismissal for failure to comply with discovery order that required non-settling plaintiffs to produce an expert report)); *Dzik v. Bayer Corp.*, 846 F.3d 211, 216 (7th Cir. 2017) (“District courts handling complex, multidistrict litigation must be given wide latitude with regard to case management in order to achieve efficiency” (internal quotation marks omitted)) (affirming MDL court’s dismissal for failure to comply with discovery order); *In re Vioxx Prod. Liab. Litig.*, 388 Fed. App’x 391 (5th Cir. 2010) (“[I]t is within a court’s discretion to take steps to manage the complex and potentially very burdensome discovery that the cases would require” (internal quotations and citations omitted)) (affirming MDL court’s dismissal for failure to comply with discovery order that required non-settling plaintiffs to produce a specific-causation expert report); *Acuna v. Brown & Root, Inc.*, 200 F.3d 335, 340 (5th Cir. 2000) (Case management “orders are designed to handle the complex issues and potential burdens on defendants and the court in mass tort litigation. In the federal courts, such orders are issued under the wide discretion afforded district judges over the management of discovery under Fed. R. Civ. P. 16.”).

² See, e.g., Case Management Order No. 57, *In re 3M Combat Arms Earplug Prods. Liab. Litig.*, MDL No. 2885 (Case No. 3:19-md-02885) (N.D. Fla. 2023) (in settlement context, requiring non-settling plaintiffs to produce medical records and expert reports); Case Management Order No. 11, Docket No. 12902, *In re: Xarelto (Rivaroxaban) Prod. Liab. Litig.*, MDL No. 2592 (Case No. 2:14-md-02592), (E.D. La. 2019) (in settlement context, requiring non-settling plaintiffs to produce medical and pharmacy records and a specific-causation expert report), available at <https://www.laed.uscourts.gov/sites/default/files/xarelto/12902.pdf>; Pretrial Order No. 18 at 2, 7-9, Docket No. 758, *In re: Fluoroquinolone Prods. Liab. Litig.*, MDL No. 2642 (Case No. 0:15-md-02642), (D. Minn. January 2, 2019) (in settlement context, requiring non-settling plaintiffs to produce medical and pharmacy records and causation and liability expert reports and bifurcated discovery on statute of limitations and other time-based defenses), available at <https://ecf.mnd.uscourts.gov/doc1/10117574348>; Case Management Order No. 126 at 2, 6-8, Docket No. 2716, *In re Testosterone Replacement Therapy Prods. Liab. Litig.*, MDL No. 2545 (Case No. 1:14-cv-01748), (N.D. Ill. June 11, 2018) (in settlement context, requiring non-settling plaintiffs to produce medical and pharmacy records and causation and liability expert reports and bifurcated discovery on statute of limitations and other time-based defenses), available at <https://lonepineorders.law.stanford.edu/wp-content/uploads/In-Re-Testosterone-Replacement-Therapy-Products-Liability-Litigation.pdf>; *In re American Med. Sys., Inc. Pelvic Repair Sys. Prods. Liab. Litig.*, MDL No. 2325, Pretrial Order # 239, ECF No. 4272 (S.D.W. Va. June 7, 2017) (establishing requirements for future claims against a defendant due to “recent settlement developments” of thousands of claims after more than three years of litigation); Case Management Order No. 78 at 5, Docket No. 519, *In re Pradaxa (Dabigatran Etexilate) Prods. Liab. Litig.*, MDL No. 2385 (Case No. 3:12-md-2385) (S.D. Ill. May 29, 2014) (in settlement context, requiring non-settling plaintiffs to produce causation expert reports), available at <http://www.ilsd.uscourts.gov/documents/mdl2385/CMO78.pdf>; Pretrial Order #28 and #29, Docket Nos. 12962, 12963, *In re Vioxx Prods. Liab. Litig.*, MDL No. 1657 (E.D. La. 2008), available at

8. Moreover, the Court finds it particularly appropriate to enter this Docket Control Order so the Court can efficiently manage an MDL that is proceeding on a settlement front with certain defendants. Several other MDL courts have recently exercised their discretion and inherent authority to enter orders establishing certain discovery and other requirements for future cases filed against certain settling defendants (but not against other non-settling defendants) in tort litigation regarding transvaginal mesh (the “AMS Mesh MDL”), testosterone replacement therapy products (the “TRT MDL”), and fluoroquinolone antibiotics (the “FQ MDL”).

The AMS Mesh MDL was one of seven centralized MDL proceedings pending before Judge Goodwin in the Southern District of West Virginia arising from different mesh products manufactured by different defendants. *See* Pretrial Order No. 239, Docket No. 4272, *In re Am. Med. Sys., Inc. Pelvic Repair Systems Prods. Liab. Litig.*, MDL No. 2325 (Case No. 2:12-md-2325), (S.D. W.Va. June 7, 2017). The court explained that it was establishing these requirements for future claims against the AMS defendants only due to “recent settlement developments,” in particular a “dramatic[]” decline in the number of cases against AMS on the active docket “[a]s a result of AMS's efforts and those of multiple counsel for plaintiffs.” *Id.* at 1-2. The court recognized that:

[C]ase management is of the utmost importance and the Court is vested with substantial discretion to manage discovery and set deadlines that will help secure “the just, speedy, and inexpensive determination of every action and proceeding.”

Id. at 2 (citation omitted). The parties’ significant progress in resolving existing claims made it appropriate to establish requirements for the speedy and just resolution of any future claims. *See id.* at 2. These requirements included expert disclosures regarding causation, among other items,

<http://www.laed.uscourts.gov/sites/default/files/vioxx/orders/vioxx.pto28.mdl.pdf> and
<http://www.laed.uscourts.gov/sites/default/files/vioxx/orders/vioxx.pto29.mdl.pdf>.

for newly filed cases. *See id.* at 3-7. Those requirements were not at that time applied to claims against non-settling defendants.

The TRT MDL is an MDL proceeding pending before Judge Kennelly in the Northern District of Illinois arising from different testosterone replacement products manufactured by different defendants. Case Management Order No. 126 at 2, Docket No. 2716, *In re Testosterone Replacement Therapy Prods. Liab. Litig.*, MDL No. 2545 (Case No. 1:14-cv-01748), (N.D. Ill. June 11, 2018). The FQ MDL is an MDL proceeding pending before Judge Tunheim in the District of Minnesota arising from different fluoroquinolone antibiotics manufactured by different defendants. Pretrial Order No. 18 at 2, Docket No. 758, *In re: Fluoroquinolone Prods. Liab. Litig.*, MDL No. 2642 (Case No. 0:15-md-02642), (D. Minn. January 2, 2019). The TRT MDL and FQ MDL courts, following the reasoning of the AMS Mesh MDL court, and citing to much of the same appellate authority and MDL docket control orders cited herein, found it appropriate to establish the same requirements for the speedy and just resolution of any future claims against the settling defendants (but not against the non-settling defendants) as this Court finds appropriate for this MDL. *See* Case Management Order No. 126 at 6-8, Docket No. 2716, *In re Testosterone Replacement Therapy*; Pretrial Order No. 18 at 7-9, Docket No. 758, *In re Fluoroquinolone*.

In addition, more recently, MDL courts in the Xarelto® and 3M Combat Arms Earplug products liability litigations entered docket control orders containing similar requirements to those included herein. *See* Case Management Order No. 11, *In re Xarelto (Rivaroxaban) Prod. Liab. Litig.*, MDL No. 2592 (E.D. La. Mar. 25, 2019); Case Management Order No. 57, *In re 3M Combat Arms Earplug Prods. Liab. Litig.*, MDL No. 2885 (Case No. 3:19-md-02885) (N.D. Fla. 2023).

For the foregoing reasons, and other good cause appearing therefor, it is Ordered as follows:

B. Litigating Plaintiffs' Requirements to Produce Certain Specified Information Regarding Their Claims

9. **Litigating Plaintiffs' Production Requirements:** Litigating Plaintiffs shall serve the following documents and/or information upon counsel for the AstraZeneca and Merck Defendants, as applicable, by email at xPPI@arnoldporter.com:

- a. **CMO NO. 7 and CMO NO. 9 Obligations:** If not already completed, executed, and served, the Litigating Plaintiff must comply with all requirements of CMO No. 7 and CMO No. 9, as amended by CMO No. 27, including but not limited to producing all medical records that document the Litigating Plaintiff's, or if different, the associated PPI user's ("Associated User's"), alleged PPI-related injury/injuries, and pharmacy records/medical records for the Litigating Plaintiff's or the Associated User's PPI prescription(s) and/or samples.
- b. **Pharmacy Records:** All pharmacy records and medical records regarding the dispensation of any prescription medication and/or samples to the Litigating Plaintiff or the Associated User for the period from five (5) years prior to the date of the Litigating Plaintiff's or the Associated User's first use of PPIs to the present.
- c. **Medical Records:** All medical records relating to the Litigating Plaintiff or the Associated User from health care providers for the period from five (5) years prior to the date of the Litigating Plaintiff's or the Associated User's first use of PPIs to the present.
- d. **Record Collection Production:** The Litigating Plaintiff and his/her counsel shall affirmatively collect and produce such Pharmacy and Medical Records from all available sources in the Litigating Plaintiff's possession, custody or control, which includes but is not limited to any relevant Pharmacy and Medical records that can be collected from the Litigating Plaintiff's or the Associated User's medical facilities, health care providers, and/or pharmacies that treated and/or dispensed drugs to, or for, the Litigating Plaintiff or the Associated User. A Litigating Plaintiff and his/her counsel shall not be in compliance with this CMO by producing only records in the Litigating Plaintiff's or his/her counsel's current possession, or by only producing authorizations to allow the AstraZeneca and Merck Defendants to collect such records.
- e. **Affidavit:** An affidavit, signed under oath, by the Litigating Plaintiff and his/her counsel attesting to the following:
 - i. The Litigating Plaintiff has complied with all requirements of this CMO;

- ii. Records have been collected from all pharmacies that dispensed drugs to, or for, the Litigating Plaintiff or the Associated User covered by paragraph B.9.b;
 - iii. All medical records described in paragraph B.9.c. have been collected;
 - iv. All records collected have been produced pursuant to this CMO;
 - v. If any of the documents or records described in Sections B.9.a., B.9.b., or B.9.c. do not exist, then the affidavit shall state that fact and the reasons, if known, why such materials do not exist, and shall attach a “No Records Statement” from the pharmacy, medical facilities, and/or other healthcare provider; and
 - vi. For each prescription PPI product taken by the Litigating Plaintiff or the Associated User, the affidavit shall specify the corresponding FDA National Drug Code (“NDC code”) and attach a medical or pharmacy record reflecting that NDC code.
- f. **Expert Reports:** Expert reports in compliance with Federal Rule of Civil Procedure 26 as follows:
- i. A Rule 26(a)(2) expert report on general causation concerning the alleged injury/injuries.
 - ii. A Rule 26(a)(2) case-specific expert report concerning the causation of the Litigating Plaintiff’s or the Associated User’s alleged injury/injuries. The reports required by Sections B.9.f.i and this B.9.f.ii may be combined in a single report by a single expert.
 - iii. A Rule 26(a)(2) expert report on the basis for liability concerning the AstraZeneca and Merck Defendants—*e.g.*, support for allegations that the AstraZeneca and Merck Defendants’ warning label(s) were inadequate, that they failed to adequately test and/or monitor the safety of their PPI product(s), and/or that they marketed their PPI product(s) in a manner that would serve as the basis for a claim against the AstraZeneca and Merck Defendants. The requirements of this Section B.9.f.iii apply only to claims alleging kidney disease.
- g. **Retention Agreements:** Signed retention agreements between Litigating Plaintiffs’ counsel and each expert who submits a report pursuant to Section B.9.f—which shall affirm the expert’s intention to attend a deposition, *Daubert* hearing, and trial, if necessary. These retention agreements shall not be produced to the AstraZeneca and Merck Defendants with the other requirements under Paragraph 9, however, upon the AstraZeneca and Merck Defendants’ unilateral request, Litigating Plaintiffs shall provide these

retention agreements to Magistrate Judge Wettre, who shall review the retention letters *in camera* to assess their compliance with this Order.

- h. **Affidavit:** An affidavit signed by the Litigating Plaintiff and his/her counsel attesting to the following:
- i. The date the Litigating Plaintiff first learned his/her or the Associated User's alleged injury/injuries may be related to PPI use;
 - ii. How the Litigating Plaintiff first learned his/her or the Associated User's alleged injury/injuries may be related to PPI use;
 - iii. The date the Litigating Plaintiff or the Associated User first spoke to or corresponded with an attorney about potential litigation related to PPI use; and
 - iv. The date the Litigating Plaintiff first retained counsel for litigation related to PPI use.

In providing the affidavit required by this paragraph, nothing in this paragraph is intended to infringe or in any way compromise the attorney-client privilege, or require the production of documents that are protected from disclosure by the attorney client privilege, including, but not limited to attorney-client retainer agreements; as such, in the event that the information required to be included in the affidavit required by this paragraph is protected under the attorney-client privilege, the assertion of that privilege must be set forth in the affidavit.

10. **Deadline to comply:**

- a. For each Litigating Plaintiff with personal injury (and related) claims pending against one or more of the AstraZeneca and Merck Defendants as of the entry of this CMO who was eligible to participate in but elects not to settle under the voluntary settlement program, the items required by paragraph B.9 shall be produced no later than 90 days after the date such Litigating Plaintiff elects not to settle his/her claims.
- b. For each Litigating Plaintiff with personal injury (and related) claims newly filed in, removed to, or transferred to this MDL against one or more of the AstraZeneca and Merck Defendants after the entry of this CMO, the items required by paragraph B.9 shall be produced no later than 90 days after the case is filed in, removed to, or transferred to this MDL, whichever is later.

11. **Failure to comply:** The Court has established the foregoing deadlines for the purpose of ensuring that pretrial litigation against the AstraZeneca and Merck Defendants will progress as smoothly and efficiently as possible. Accordingly, the Court expects strict adherence

to these deadlines. Should any Litigating Plaintiff fail to comply with the obligations of paragraphs B.9 and B.10, or should the AstraZeneca and Merck Defendants deem the Litigating Plaintiff's compliance with this CMO deficient, counsel for the AstraZeneca and Merck Defendants shall notify the Court of the alleged deficiency and the Court shall issue an "Order To Show Cause Why the Case Should Not Be Dismissed With Prejudice." Litigating Plaintiff's counsel shall have 21 days to respond to said Order To Show Cause. If the Litigating Plaintiff fails to show cause within 21 days of entry of the Court's Order To Show Cause, the Court shall dismiss the Litigating Plaintiff's case with prejudice. *See, e.g., Freeman* 764 F.3d at 809-10; *Phenylpropanolamine*, 460 F.3d at 1232-34.

C. Expedited Case-Specific Bifurcated Discovery on Statute of Limitations, Other Time-Based Defenses, and Causation Issues and Related Dispositive Motion Practice

12. If the Parties jointly agree that Litigating Plaintiff has complied with the production requirements outlined in paragraphs B.9 and B.10, then the Parties, as applicable, shall submit a proposed Scheduling Order to the Court that: (a) grants the Parties 180 days from the entry of the Scheduling Order to conduct expedited bifurcated discovery on potentially case-dispositive issues, including case-specific statute of limitations, other time-based defenses, and causation issues ("Expedited Discovery"); and (b) sets a briefing schedule that gives the Parties 45 days from the close of Expedited Discovery for the Parties to submit summary judgment motions and *Daubert* motions, 28 days for oppositions, and 28 days for replies. The briefing schedule required by subsection (b) may not be changed absent agreement of the parties or prior leave granted by the Court upon a showing of good cause.

13. The Parties shall have 180 days to conduct Expedited Discovery on statute of limitations, other time-based defenses, and causation issues. During such Expedited Discovery, the Parties are permitted to: (a) serve written discovery related to statute of limitations, other time-

based defenses and/or case-specific affirmative defenses, and causation issues specific to the Litigating Plaintiff; (b) take the depositions of the Litigating Plaintiff, the Litigating Plaintiff's or Associated User's spouse, and any other non-party fact witness specific to the Litigating Plaintiff identified in the Plaintiff Fact Sheet or through other discovery for up to seven hours each, with counsel for the AstraZeneca and Merck Defendants, as applicable, questioning first at each deposition; (c) take the depositions of each of the Litigating Plaintiff's or Associated User's prescribing and treating healthcare providers with the issue of priority of questioning at each deposition to be subject to a meet and confer, and if necessary, resolution by the Court; and (d) take the depositions of the Litigating Plaintiff's experts who submit reports pursuant to Section B.9.f above. If the AstraZeneca and Merck Defendants serve written discovery on Litigating Plaintiffs in accordance with this Paragraph, then Litigating Plaintiffs must respond to the discovery prior to the AstraZeneca and Merck Defendants' depositions of Litigating Plaintiff or the Associated User and Litigating Plaintiff's or the Associated User's prescribing and treating healthcare providers, provided that Litigating Plaintiff shall have at least 30 days to respond to such discovery. The AstraZeneca and Merck Defendants shall provide Defendant Fact Sheets within sixty (60) days of entry of the Scheduling Order described in Paragraph C.12. If a Litigating Plaintiff serves any additional written discovery against the AstraZeneca and Merck Defendants pursuant to clause (a) above beyond a request for the Defense Fact Sheet required under CMO No. 22, the Parties shall meet and confer about an appropriate deadline for responding to such discovery, provided Defendants shall have at least 30 days to respond to such discovery. The Court's use of the term "specific to the Litigating Plaintiff" is intended to express the Court's prohibition of additional "generic" discovery against the AstraZeneca and Merck Defendants during the Expedited Discovery period. No other depositions, including depositions of current and former sales

representatives and managers of the AstraZeneca and Merck Defendants, may be taken during the Expedited Discovery period.

14. If the AstraZeneca and Merck Defendants' summary judgment motions are denied in any case, as applicable, the Court will set a Case Management Conference to determine whether any non-duplicative additional discovery is necessary and to discuss other case management issues. For any claims alleging non-kidney injuries, the parties shall meet and confer regarding an appropriate deadline by which Litigating Plaintiffs must produce a Rule 26(a)(2) expert report on the basis for liability concerning the AstraZeneca and Merck Defendants. The filing and briefing of summary judgment motions and *Daubert* motions after the Expedited Discovery discussed above shall not prejudice or otherwise foreclose the opportunity for the Parties to file later, non-duplicative summary judgment and *Daubert* motions after completing full fact and expert discovery. The Court's use of the term "non-duplicative" is intended to express the Court's intention not to permit later summary judgment motions concerning topics addressed in summary judgment motions filed at the conclusion of the Expedited Discovery period or *Daubert* motions concerning witnesses addressed in *Daubert* motions filed at the conclusion of the Expedited Discovery period.

IT IS SO ORDERED.

SIGNED 2nd day of October 2023.



CLAIRE C. CECCHI
United States District Judge